Apellis Pharmaceuticals, Inc. (APLS) Research

Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.

Market snapshot

Symbol
APLS
Price
$41.03
Day change
0.00%
Market cap
$5.3B
P/E ratio
38.80x
52-week range
16.61-41.14
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$33.40

Recent news

  • Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get

    Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.

  • Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio

    Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved.

  • Why This Pharma Stock More Than Doubled Today

    A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.

Peer companies

  • Adaptive Biotechnologies Corporation (ADPT)
  • Agios Pharmaceuticals, Inc. (AGIO)
  • Beam Therapeutics Inc. (BEAM)
  • Cidara Therapeutics, Inc. (CDTX)
  • Catalyst Pharmaceuticals, Inc. (CPRX)
  • IDEAYA Biosciences, Inc. (IDYA)
  • Kiniksa Pharmaceuticals, Ltd. (KNSA)
  • Mineralys Therapeutics, Inc. (MLYS)

Recent insider activity

  • Dunlop A. Sinclair — U-Tender (161567 shares) on 2026-05-14
  • Dunlop A. Sinclair — D-Return (3544 shares) on 2026-05-14
  • Dunlop A. Sinclair — D-Return (14684 shares) on 2026-05-14
  • Dunlop A. Sinclair — D-Return (27600 shares) on 2026-05-14
  • Dunlop A. Sinclair — D-Return (11199 shares) on 2026-05-14

Open Apellis Pharmaceuticals, Inc. (APLS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.